December 27, 2017 / 2:12 PM / a year ago

BRIEF-Biondvax Plans Phase 3 Clinical Trial Following Receipt Of Scientific Advice From The European Medicines Agency

Dec 27 (Reuters) - Biondvax Pharmaceuticals Ltd:

* BIONDVAX PLANS PHASE 3 CLINICAL TRIAL FOLLOWING RECEIPT OF SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY (EMA)

* BIONDVAX PHARMACEUTICALS - M-001​ PHASE 3 TRIAL EXPECTED TO TAKE PLACE IN EASTERN EUROPE & BEGIN PRIOR TO 2018/19 FLU SEASON

* BIONDVAX-‍EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ADVICE TO FACILITATE PROCEDURES IN COUNTRIES WHERE PHASE 3 STUDY WILL TAKE PLACE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below